Paul Lingor, MD

Paul Lingor, MD, is Professor for Neurology, Group Leader and Head of the Outpatient Clinics for Motoneuron Disorders and Co-head of the Outpatient Clinics for Movement Disorders and at the Department of Neurology of the TUM Klinikum Rechts der Isar in Munich, Germany. He is a translational neuroscientist with interest in Parkinson’s disease and Amyotrophic Lateral Sclerosis. In both diseases, his group works on an improved diagnosis using molecular biomarkers and leverages the potential of tear fluid. Because tear fluid can be collected non-invasively, repeatedly and with little discomfort to the patients, this biomaterial recently received much attention for the analysis of proteins, including aggregated species. The Lingor group is also interested in the development of novel therapies, focusing on drug repurposing. Currently, the clinical phase IIa ROCK-PD study evaluates the safety, tolerability and efficacy of Fasudil in patients with Parkinson’s disease.